当前位置：   首页 > 需求大厅

 >  生产研发 

招募急性痛风性关节炎志愿者 招募概述： 如果您是急性痛风性关节炎患者，符合以下条件就可以报名参加虎贞痛风胶囊的临床研究。虎贞痛风胶囊由广东一力集团制药有限公司/广州暨南生物医药研究开发基地有限公司研制并提供的，并于2008年经国家食品药品监督管理局批准进行临床研究，临床试验批件号：2008L02043。其具有清热利湿，化瘀利浊，滋补肝肾的功效。主治急性痛风性关节炎（湿热蕴结证），症见：关节红肿热痛，伴有发热，汗出不解，口渴喜饮，心烦不安，小便黄及痛风病见上述症候者。此研究由中国中医科学院广安门医院等15家医院共同参与。 如果您愿意参加本项研究并通过筛选符合条件，我们将为您提供3天的免费治疗并免费进行相关检查（包含：体格检查、血常规、尿常规、便常规、肝肾功、心电图、血尿酸、类风湿因子、血沉、C反应蛋白和抗链球菌溶血素‘O’）。 入选条件： 1.符合急性痛风性关节炎诊断标准，且辨证为湿热蕴结证。 2.急性发作在48小时之内，本次发作未用过治疗药（包括秋水仙碱、非甾类抗炎药及激素等）者。 3.VAS评分≥4分。 4.年龄18-65岁。 5.签署知情同意书。 您一旦参加本试验将获得较全面的检查和试验药物治疗，并将得到医生的全面跟踪随访。 如您符合纳入标准，并有意参加本研究项目，请到辽宁中医药大学第二附属医院住院部A楼三楼糖尿病科咨询 。 地址：沈阳市皇姑区黄河北大街60号 联系方式：江红主任：138 4008 4568 马尧医生：139 4046 6290   [更多]

日本住友药业的注射用美罗培南说明书，要CFDA今年批准修订的最新版本的。   [更多]

在合理合法的范围内   [更多]

成本，生产周期，产品质量，工艺规模请列出。   [更多]

设备应能至少每分钟测量血含量两次，连续测量时间至少60分钟。探头小巧并方便弯曲，准确度：设备必须能够衡量的范围为0 - 1.25毫升的血（稀释在大约15 - 30毫升的盐水中），精度要测准大约6µl的血（稀释在大约15 - 30毫升的盐水中）。 具体如下：https://www.innocentive.com/ar/challenge/9933690 The Seeker desires a device to continuously and/or repeatedly measure the amount of blood in a volume of saline. The device should be capable of measuring at least twice per minute for at least 60 minutes. This is a Reduction-to-Practice Challenge that requires a written proposal, experimental proof-of-concept data, and prototype delivery if requested Source: InnoCentive Challenge ID: 9933690 Challenge Overview The Seeker is looking for a device to continuously measure blood content in a small volume of saline. Blood is introduced continuously through a thin, flexible probe placed in the container of saline and the device must be able to measure the overall blood content in the container at least twice per minute for at least 60 minutes. The device must be able to measure over the range of 0 – 1.25 ml of blood in approximately 15 – 30 ml of saline with an accuracy of approximately 6 µl of blood. Only minimal stirring is allowed, thus devices should not rely on an assumption of uniform mixing of the blood in the saline solution. The rate of blood introduction may vary significantly, and may start and stop numerous times. The submission to the Challenge should include the following: The detailed description of the proposed Solution addressing specific Solution Requirements presented in the Detailed Description of the Challenge. This description should be accompanied by a well-articulated rationale supported by literature/patent precedents. Experimental proof-of-concept data obtained as outlined in the Detailed Description of the Challenge (and delivery of a prototype if requested by the Seeker).   [更多]

罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展，即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元，开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]

肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前，我们的治疗方法很有限，寻找治疗方法的大多数临床试验都失败了，部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物，对提高疾病的可控性会有很大的帮助，定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]

不能控制其发作的癫痫猝死（SUDEP）是导致年轻人死亡的主要原因。每年超过千分之一的癫痫患者死于猝死，如果是不受控制的癫痫发作，风险会增加一百五十分之一。一种普遍恐惧的意识和持续受到的歧视导致太多的人隐藏自己的癫痫病情而没有接受持续治疗或寻求更有效的治疗方法。这增加了他们癫痫猝死的风险 癫痫基金会帮助机构决心改变这种状况，开展一个创意的宣传活动，鼓励人们寻求最佳的癫痫发作和癫痫发作控制和教育他们自己和他们的家庭以及他们如何可以减轻癫痫猝死的风险。此外，这个活动应该邀请更广泛的医疗保健社区讨论SUDEP，明白不接受持续发作的重要性，并寻找一种更有效的治疗方法。具体（https://www.innocentive.com/ar/challenge/9933717）如下 TAGS: Global Health, Business/Entrepreneurship, Life Sciences, Scientific American, Ideation AWARD: $15,000 USD | DEADLINE: 7/13/15 | ACTIVE SOLVERS: 12 | POSTED: 6/09/15 Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in young adults who have epilepsy and cannot control their seizures. Each year, more than 1 out of 1,000 people with epilepsy die from SUDEP, and, if seizures are uncontrolled, the risk increases to more than 1 out of 150. A widespread lack of awareness and ongoing fear and discrimination lead too many individuals to hide their epilepsy and to accept ongoing seizures instead of seeking out more effective treatments. This increases their risk of SUDEP. The Epilepsy Foundation SUDEP Institute is determined to change this and is challenging Solvers to come up with ideas for a creative advocacy campaign that encourages people with seizures and epilepsy to seek optimal seizure control and to educate themselves and their families about SUDEP and how they can mitigate its risks. In addition, the campaign should invite the broader health care community to talk about SUDEP, understand the importance of not accepting ongoing seizures, and pursue all effective treatment options. Can you help us to demystify seizures and epilepsy, and empower people with epilepsy? This is an Ideation Challenge with a guaranteed award for at least one submitted solution.   [更多]

合理的大生产工艺即可或中试工艺   [更多]

阿斯利康提出需求：在大多数的慢性肾脏疾病的情况下有关肾小球滤过屏障功能受损的研究。缺少良好的肾小球体外模型，就不能在细胞学和病理学的范畴详细理解肾小球的功能。 阿斯利康正在寻找方法来开发一个肾小球模型系统。理想情况下,体外模型应该包含一个独立的微型药学单元，有适当的介质，流体流动和所受压力。可以调整模拟体内黏膜所需条件属性，最终建立形成一个功能肾小球滤过屏障。 具体看下面内容： https://www.innocentive.com/ar/challenge/9933748The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier function is compromised. However, a detailed cellular understanding of the functioning and pathology of the glomerulus has been limited by the lack of good in vitro models of glomerular function. AstraZeneca is looking for approaches to develop a glomerular model system. Ideally, the in vitro model should incorporate a self-contained microphysiological unit where biologically appropriate media, fluid flow and shear stress can be modulated to simulate in vivo properties that will ultimately recapitulate the conditions necessary for endothelial and podocyte cell types to form a functional glomerular filtration barrier. This is an ideation challenge and only requires a written solution. Source: InnoCentive Challenge ID: 9933748 Challenge Overview The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier is compromised. The coordinated efforts of the podocytes and endothelium together with their underlying basement membrane establish the glomerular filtration barrier and injury to these cells can lead to loss of kidney function. There are currently no human in vitro models that mimic a functional or diseased glomerulus. Development of a human glomerular filtration barrier biomimetic system will thus address gaps in in vitro models for simulating human kidney disease, toxicity and DMPK. We are looking for innovative approaches to developing a glomerular model that incorporates a self-contained microphysiological unit, ideally including podocytes, the endothelium, and   [更多]